- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05889741
Kombinerer Stellate Ganglion Block med langvarig eksponering for PTSD
Kombinere Stellate Ganglion Block med langvarig eksponering for PTSD: En randomisert klinisk studie
The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.
The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.
Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Amanda Flores
- Telefonnummer: 210-562-6726
- E-post: floresa13@uthscsa.edu
Studiesteder
-
-
Texas
-
Fort Hood, Texas, Forente stater, 76544
- Rekruttering
- Carl R. Darnall Army Medical Center
-
Ta kontakt med:
- Paul Fowler
- Telefonnummer: 726-225-5520
- E-post: fowlerp@uthscsa.edu
-
Hovedetterforsker:
- Caleb Dickinson, DO
-
Fort Sam Houston, Texas, Forente stater, 78234
- Rekruttering
- Brook Army Medical Center (BAMC)
-
Ta kontakt med:
- Wilson B Pfeiffer, DO
- Telefonnummer: 210-916-8256
- E-post: wilson.b.pfeiffer.mil@health.mil
-
Hovedetterforsker:
- Wilson B Pfeiffer, Do
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- University of Texas Health Science Center at San Antonio
-
Ta kontakt med:
- Amanda Flores
- Telefonnummer: 210-562-6726
- E-post: floresa13@uthscsa.edu
-
Hovedetterforsker:
- Alan Peterson, PhD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Active duty and retired military service members ages 18-65 years
- PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale
- Able to speak and read English (due to standardization of outcome measures)
- Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed.
Exclusion Criteria:
- Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider.
- Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment)
- Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment.
- Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
- Pregnancy or breastfeeding
- Current anticoagulant use
- History of bleeding disorder
- Infection or mass at injection site
- Myocardial infarction within 6 months of procedure
- Pathologic bradycardia or irregularities of heart rate or rhythm
- Symptomatic hypotension
- Phrenic or laryngeal nerve palsy
- History of glaucoma
- Uncontrolled seizure disorder
- History of allergy to local anesthetics
- Current use of Class III antiarrhythmics
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Stellate Ganglion Block
One time administration of a stellate ganglion block |
6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
Andre navn:
|
|
Placebo komparator: Sham SGB
One time administration |
6.5cc of Normal Saline one time into the stellate ganglion. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient Health Questionnaire-9 items (PHQ-9)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
General Anxiety Disorder Screener - 7 Items (GAD-7)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Posttraumatic Cognitions Inventory (PTCI)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Psychophysiological arousal - Galvanic Skin Response
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring galvanic skin response |
Two weeks
|
|
Psychophysiological arousal - Skin Temperature
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring skin temperature |
Two weeks
|
|
Psychophysiological arousal - Heart Rate
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring heart rate |
Two weeks
|
|
Psychophysiological arousal - Interbeat Interval
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring interbeat interval |
Two weeks
|
|
Psychophysiological arousal - Three-Dimensional Accelerometer Movement
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement |
Two weeks
|
|
Psychophysiological arousal - Electrodermal Activity
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring electrodermal activity |
Two weeks
|
|
Psychophysiological arousal - Photoplethysmography
Tidsramme: Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring photoplethysmography |
Two weeks
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Alan Peterson, PhD, The University of Texas Health Science Center at San Antonio
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Lipov EG, Joshi JR, Lipov S, Sanders SE, Siroko MK. Cervical sympathetic blockade in a patient with post-traumatic stress disorder: a case report. Ann Clin Psychiatry. 2008 Oct-Dec;20(4):227-8. doi: 10.1080/10401230802435518. No abstract available.
- Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF. Effect of Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic Stress Disorder. Mil Med. 2016 Sep;181(9):1135-41. doi: 10.7205/MILMED-D-15-00518.
- Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med. 2014 Oct;179(10):1133-40. doi: 10.7205/MILMED-D-14-00151.
- Hanling SR, Hickey A, Lesnik I, Hackworth RJ, Stedje-Larsen E, Drastal CA, McLay RN. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med. 2016 Jul-Aug;41(4):494-500. doi: 10.1097/AAP.0000000000000402.
- Odosso RJ, Petta L. The Efficacy of the Stellate Ganglion Block as a Treatment Modality for Posttraumatic Stress Disorder Among Active Duty Combat Veterans: A Pilot Program Evaluation. Mil Med. 2021 Jul 1;186(7-8):e796-e803. doi: 10.1093/milmed/usaa246.
- Peterson AL, Blount TH, Foa EB, Brown LA, McLean CP, Mintz J, Schobitz RP, DeBeer BR, Mignogna J, Fina BA, Evans WR, Synett S, Hall-Clark BN, Rentz TO, Schrader C, Yarvis JS, Dondanville KA, Hansen H, Jacoby VM, Lara-Ruiz J, Straud CL, Hale WJ, Shah D, Koch LM, Gerwell KM, Young-McCaughan S, Litz BT, Meyer EC, Blankenship AE, Williamson DE, Roache JD, Javors MA, Sharrieff AM, Niles BL, Keane TM; Consortium to Alleviate PTSD. Massed vs Intensive Outpatient Prolonged Exposure for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 3;6(1):e2249422. doi: 10.1001/jamanetworkopen.2022.49422.
- Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, Mintz J, Young-McCaughan S, Borah EV, Dondanville KA, Fina BA, Hall-Clark BN, Lichner T, Litz BT, Roache J, Wright EC, Peterson AL; STRONG STAR Consortium. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018 Jan 23;319(4):354-364. doi: 10.1001/jama.2017.21242.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HSC20230087H
- W81XWH2220055 (Annet stipend/finansieringsnummer: Department of Defense)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .